Intuitive Surgical (ISRG) consistently demonstrated
strong performance in Q2 2024, exceeding profit forecasts and prompting a surge in its share price. The demand for its
robotic devices and
surgical robots, such as the
da Vinci 5, has escalated. Analysts anticipate continued momentum despite potential headwinds. Due in large part to the success of its Q2 earnings,
Intuitive Surgical's stock has reached a record high and analysts have raised its price targets.
Morgan Stanley and
Barclays increased ISRG's price target to $460.00 and $490.00, respectively. Wall Street maintains a bullish view, with Jim Cramer encouraging investors to purchase ISRG, and
Ray Dalio also recommending this growth stock. The FDA has granted clearance for Intuitive Surgical's new operations which has led to another breakout. While some expect Intuitive Surgical to be a millionaire-maker stock, it has been branded as both an expensive and extremely risky investment.
Intuitive Surgical ISRG News Analytics from Tue, 23 Jan 2024 08:00:00 GMT to Sun, 21 Jul 2024 15:23:11 GMT -
Rumor -8
